aTyr Pharma

aTyr Pharma is a biotherapeutics company that is focused on developing innovative medicines based on novel biology. The company, listed on Nasdaq under the symbol LIFE, is dedicated to the discovery and development of medicines based on novel biological pathways, particularly the extracellular functionality and signaling pathways of tRNA synthetases. With a robust global intellectual property estate, aTyr Pharma has directed its efforts towards a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. The company's primary focus is on their clinical-stage product candidate efzofitimod (ATYR1923), designed to bind to the neuropilin-2 receptor and down-regulate immune engagement in severe inflammatory lung diseases. The company was founded in 2005 by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., who are leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In a recent development, aTyr Pharma secured a $50.00M Post-IPO Equity investment on 08 February 2023. For more information about the company, please visit http://www.atyrpharma.com. With its innovative approach to drug development, aTyr Pharma presents an exciting opportunity for investors looking to be part of cutting-edge advancements in the biotechnology and pharmaceutical industries.